Lubiprostone (DrugBank: Lubiprostone)
4 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 4 |
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 290 | 非特異性多発性小腸潰瘍症 | 1 |
| 299 | 嚢胞性線維症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000022022 | 2016/05/10 | 10/05/2016 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | Parkinson diseaseChronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment | Dokkyo Medical University | NULL | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan |
| 2 | JPRN-UMIN000022023 | 2016/05/10 | 10/05/2016 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- | Parkinson diseaseChronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen | Dokkyo Medical University | NULL | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan | |
| 3 | NCT00669461 (ClinicalTrials.gov) | June 2009 | 28/4/2008 | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Constipation;Parkinson's Disease | Drug: Lubiprostone | University of Arkansas | Takeda | Terminated | 50 Years | 85 Years | All | 1 | N/A | United States |
| 4 | NCT00908076 (ClinicalTrials.gov) | February 2009 | 21/5/2009 | Amitiza in Constipation Associated With PD (Parkinson's Disease) | Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease | Parkinson's Disease | Drug: LUBIPROSTONE | Baylor College of Medicine | University of South Florida | Completed | 18 Years | 85 Years | All | 78 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01236534 (ClinicalTrials.gov) | November 2010 | 4/11/2010 | Lubiprostone in Patients With Multiple Sclerosis Associated Constipation | Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation | Multiple Sclerosis;Constipation | Drug: Lubiprostone;Drug: Placebo | University of Rochester | Takeda | Completed | 18 Years | N/A | All | 21 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000030327 | 2017/12/25 | 22/12/2017 | Proof-of-concept clinical trial of lubiprostone's effect on chronic enteropathy associated with SLCO2A1 | Proof-of-concept clinical trial of lubiprostone's effect on chronic enteropathy associated with SLCO2A1 - LEAC study | Nonspecific multiple ulcers in the small intestine unrelated to NSAID (Chronic enteropathy associated with SLCO2A1: CEAS) | lubiprostone(12 micrograms) for 8 weeks | Fujita Health University, Department of Gastroenterology | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 8 | Phase 1;Phase 2 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00706004 (ClinicalTrials.gov) | July 2008 | 25/6/2008 | Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis | Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis | Constipation;Cystic Fibrosis | Drug: lubiprostone | University of Arkansas | Takeda Pharmaceuticals North America, Inc. | Completed | 18 Years | N/A | All | 9 | N/A | United States |